Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: A California Cancer Consortium trial

George Somlo; Ashkan Lashkari; William Bellamy; Todd M. Zimmerman; Joseph Tuscano; Margaret R. O'Donnell; Ann F. Mohrbacher; Stephen J. Forman; Paul Frankel; Helen X. Chen; James H. Doroshow; David R Gandara

doi:10.1111/j.1365-2141.2011.08623.x

Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: A California Cancer Consortium trial

George Somlo, Ashkan Lashkari, William Bellamy, Todd M. Zimmerman, Joseph Tuscano, Margaret R. O'Donnell, Ann F. Mohrbacher, Stephen J. Forman, Paul Frankel, Helen X. Chen, James H. Doroshow, David R Gandara

Hematology and Oncology

Research output: Contribution to journal › Article

33 Scopus citations

Original language	English (US)
Pages (from-to)	533-535
Number of pages	3
Journal	British Journal of Haematology
Volume	154
Issue number	4
DOIs	https://doi.org/10.1111/j.1365-2141.2011.08623.x
State	Published - Aug 2011

Keywords

Angiogenesis
Bevacizumab
Multiple myeloma
Thalidomide
Vascular endothelial growth factor

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/j.1365-2141.2011.08623.x

Cite this

Somlo, G., Lashkari, A., Bellamy, W., Zimmerman, T. M., Tuscano, J., O'Donnell, M. R., Mohrbacher, A. F., Forman, S. J., Frankel, P., Chen, H. X., Doroshow, J. H., & Gandara, D. R. (2011). Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: A California Cancer Consortium trial. British Journal of Haematology, 154(4), 533-535. https://doi.org/10.1111/j.1365-2141.2011.08623.x

Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma : A California Cancer Consortium trial. / Somlo, George; Lashkari, Ashkan; Bellamy, William; Zimmerman, Todd M.; Tuscano, Joseph; O'Donnell, Margaret R.; Mohrbacher, Ann F.; Forman, Stephen J.; Frankel, Paul; Chen, Helen X.; Doroshow, James H.; Gandara, David R.

In: British Journal of Haematology, Vol. 154, No. 4, 08.2011, p. 533-535.

Research output: Contribution to journal › Article

Somlo, G, Lashkari, A, Bellamy, W, Zimmerman, TM, Tuscano, J, O'Donnell, MR, Mohrbacher, AF, Forman, SJ, Frankel, P, Chen, HX, Doroshow, JH & Gandara, DR 2011, 'Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: A California Cancer Consortium trial', British Journal of Haematology, vol. 154, no. 4, pp. 533-535. https://doi.org/10.1111/j.1365-2141.2011.08623.x

Somlo, George ; Lashkari, Ashkan ; Bellamy, William ; Zimmerman, Todd M. ; Tuscano, Joseph ; O'Donnell, Margaret R. ; Mohrbacher, Ann F. ; Forman, Stephen J. ; Frankel, Paul ; Chen, Helen X. ; Doroshow, James H. ; Gandara, David R. / Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma : A California Cancer Consortium trial. In: British Journal of Haematology. 2011 ; Vol. 154, No. 4. pp. 533-535.

@article{9a064c793796494898844c3a81c1b6e8,

title = "Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: A California Cancer Consortium trial",

keywords = "Angiogenesis, Bevacizumab, Multiple myeloma, Thalidomide, Vascular endothelial growth factor",

author = "George Somlo and Ashkan Lashkari and William Bellamy and Zimmerman, {Todd M.} and Joseph Tuscano and O'Donnell, {Margaret R.} and Mohrbacher, {Ann F.} and Forman, {Stephen J.} and Paul Frankel and Chen, {Helen X.} and Doroshow, {James H.} and Gandara, {David R}",

year = "2011",

month = aug,

doi = "10.1111/j.1365-2141.2011.08623.x",

language = "English (US)",

volume = "154",

pages = "533--535",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma

T2 - A California Cancer Consortium trial

AU - Somlo, George

AU - Lashkari, Ashkan

AU - Bellamy, William

AU - Zimmerman, Todd M.

AU - Tuscano, Joseph

AU - O'Donnell, Margaret R.

AU - Mohrbacher, Ann F.

AU - Forman, Stephen J.

AU - Frankel, Paul

AU - Chen, Helen X.

AU - Doroshow, James H.

AU - Gandara, David R

PY - 2011/8

Y1 - 2011/8

KW - Angiogenesis

KW - Bevacizumab

KW - Multiple myeloma

KW - Thalidomide

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=79960846565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960846565&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2011.08623.x

DO - 10.1111/j.1365-2141.2011.08623.x

M3 - Article

C2 - 21517811

AN - SCOPUS:79960846565

VL - 154

SP - 533

EP - 535

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -